Abstract
Metaiodobenzylguanidine (MIBG, iobenguane) is a guanethidine analogue that targets the norepinephrine transporter and, when radiolabeled with the beta-emitter I-131, has been used with varying protocols to treat neuroendocrine tumors, including pheochromocytoma/paraganglioma (PPGL) around the globe for more than 35 years. In 2018 a high specific activity formulation (Azedra®) became the first, and currently only, Food and Drug Administration approved drug to treat unresectable, locally advanced, or metastatic PPGL. This editorial will discuss the operational aspects of clinical implementation and use of HSA 131I-MIBG in advanced PPGL patients.
- Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.